Esther Bommer
Research Subjects
Esther Bommer has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Peixoto
Pharmacology and Structural Biology, Toulouse University, CNRS, Toulouse, France
14 shared publications - Carina Hage
Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany
14 shared publications - Christian Klein
Faculty for Chemistry and Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany
14 shared publications - Emilio Yángüez
Roche Innovation Center Zurich, Schlieren, Switzerland
14 shared publications - Iryna Dekhtiarenko
Roche Innovation Center Zurich, Schlieren, Switzerland
14 shared publications - Klas Hatje
Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland
14 shared publications
Latest Publications
- Open Access
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Binding contributions of the PD-1 and LAG-3 arms of tobemstomig.
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Binding contributions of the PD-1 and LAG-3 arms of tobemstomig.
- Open Access
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Tobemstomig maintains long-term stem-like T cells and their progeny
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Tobemstomig maintains long-term stem-like T cells and their progeny
- Open Access
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
In-vivo and ex-vivo preferential binding of tobemstomig
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
In-vivo and ex-vivo preferential binding of tobemstomig
- Open Access
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
In vivo tobemstomig preferentially binds and expands CD8 TILs including PD-1+ TCF-1+ stem-like T cells and drives their differentiation toward cytotoxic effectors. In vivo efficacy study and immunopharmacodynamic in human PD-1 and human LAG-3 double transgenic mice bearing subcutaneous Panc02-H7-Fluc tumors treated for 2 weeks with the indicated treatments. A, Tumor growth curves (n = 12 mice per treatment group; mean ± SEM). B and C, Representative contour plots of frequencies of CD8 and CD4 TILs (top), PGLALA+ PD-1+ CD8+ TILs (middle), and PGLALA+ PD-1+ CD4+ TILs (bottom) in one mouse of four. D, Pie chart depicting dose-dependent binding of tobemstomig as PGLALA+, available target, and target-negative cells within CD8 and CD4 TILs. E–L, Immunopharmacodynamic analysis of the effect of tobemstomig vs. parental anti–PD-1 (aPD-1) on (E) CD8, (F) CD4 T cells, and (G) Treg counts within the tumor microenvironment, (H) CD8:Treg ratio, (I) frequencies of PD-1+ CD8 TILs, (J) amount of stem-like (PD-1+ TCF-1+) CD8 T cells, and (K and L) progeny (n = 4; box plots represent median, minimum/maximum, and individual points). Statistical comparisons were performed using one-way ANOVA with the Tukey multiple comparison test (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
In vivo tobemstomig preferentially binds and expands CD8 TILs including PD-1+ TCF-1+ stem-like T cells and drives their differentiation toward cytotoxic effectors. In vivo efficacy study and immunopharmacodynamic in human PD-1 and human LAG-3 double transgenic mice bearing subcutaneous Panc02-H7-Fluc tumors treated for 2 weeks with the indicated treatments. A, Tumor growth curves (n = 12 mice per treatment group; mean ± SEM). B and C, Representative contour plots of frequencies of CD8 and CD4 TILs (top), PGLALA+ PD-1+ CD8+ TILs (middle), and PGLALA+ PD-1+ CD4+ TILs (bottom) in one mouse of four. D, Pie chart depicting dose-dependent binding of tobemstomig as PGLALA+, available target, and target-negative cells within CD8 and CD4 TILs. E–L, Immunopharmacodynamic analysis of the effect of tobemstomig vs. parental anti–PD-1 (aPD-1) on (E) CD8, (F) CD4 T cells, and (G) Treg counts within the tumor microenvironment, (H) CD8:Treg ratio, (I) frequencies of PD-1+ CD8 TILs, (J) amount of stem-like (PD-1+ TCF-1+) CD8 T cells, and (K and L) progeny (n = 4; box plots represent median, minimum/maximum, and individual points). Statistical comparisons were performed using one-way ANOVA with the Tukey multiple comparison test (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
- Open Access
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
In-vivo dose dependent preferential binding of tobemstomig
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
In-vivo dose dependent preferential binding of tobemstomig
- Open Access
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Tobemstomig is refractory to drug-shaving by macrophages
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Tobemstomig is refractory to drug-shaving by macrophages
- Open Access
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Intratumoral stem-like T cells retain their profile upon tobemstomig treatment
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Intratumoral stem-like T cells retain their profile upon tobemstomig treatment
- Open Access
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Intratumoral PD-1+ TCF-1+ stem-like CD8 T cells retain their transcriptional characteristics upon treatment with mu-tobemstomig. Immunopharmacodynamic study on the effect of different therapies, given three times, on amounts, phenotype, effector function, and molecular signature of intratumoral CD8 T cells obtained from human PD-1 and human LAG-3 double transgenic mice bearing subcutaneous Panc02-H7-Fluc tumors. A, Representative contour plots of the frequencies of PD-1+ CD8 TILs expressing TCF-1 (stem-like) vs. TIM-3 (progeny). Amounts of intratumoral PD-1+ CD8 TILs expressing TCF-1 vs. TIM-3 (B) at day 28 and (C) day 37 (n = 4, stacked bars; mean ± SEM). D, Two-dimensional Uniform Manifold Approximation and Projection for Dimension Reduction (UMAP) visualization of CD8+ TILs colored according to the subset (left) and specific treatment effect (right). E, Expression of selected markers and signatures among CD8+ TILs using a 2D UMAP visualization. F, Average signature enrichment scores among CD8 T cells per treatment group and individual animal (3–4 mice per group; box plots represent median, minimum/maximum, and individual points). G, Pie chart represents relative cell-type composition per treatment group.
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Intratumoral PD-1+ TCF-1+ stem-like CD8 T cells retain their transcriptional characteristics upon treatment with mu-tobemstomig. Immunopharmacodynamic study on the effect of different therapies, given three times, on amounts, phenotype, effector function, and molecular signature of intratumoral CD8 T cells obtained from human PD-1 and human LAG-3 double transgenic mice bearing subcutaneous Panc02-H7-Fluc tumors. A, Representative contour plots of the frequencies of PD-1+ CD8 TILs expressing TCF-1 (stem-like) vs. TIM-3 (progeny). Amounts of intratumoral PD-1+ CD8 TILs expressing TCF-1 vs. TIM-3 (B) at day 28 and (C) day 37 (n = 4, stacked bars; mean ± SEM). D, Two-dimensional Uniform Manifold Approximation and Projection for Dimension Reduction (UMAP) visualization of CD8+ TILs colored according to the subset (left) and specific treatment effect (right). E, Expression of selected markers and signatures among CD8+ TILs using a 2D UMAP visualization. F, Average signature enrichment scores among CD8 T cells per treatment group and individual animal (3–4 mice per group; box plots represent median, minimum/maximum, and individual points). G, Pie chart represents relative cell-type composition per treatment group.
- Open Access
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Tobemstomig maintains long-term PD-1+ TCF-1+ CD8 T cells and their progeny in the tumor. In vivo efficacy study and immunopharmacodynamic in human PD-1 and human LAG-3 double transgenic mice bearing subcutaneous Panc02-H7-Fluc tumors treated for 3 weeks with the indicated treatments. Tumor growth curves in mice receiving (A) mu-tobemstomig, (B) mu-nivolumab, (C) mu-relatlimab–like anti–LAG-3, and (D) mu-nivolumab in combination with mu-relatlimab–like anti–LAG-3 (n = 10 mice per treatment group, mean ± SEM). E, Amount of intratumoral T cells, (F) amount of intratumoral CD4 T cells, (G) frequency of Tconv cells (CD4+ FOXP3−), (H) frequency of Tregs (CD4+ FOXP3+), (I) Tconv:Treg ratio, (J) CD8:Treg ratio within the tumor of mice sacrificed on day 28, (K) amount of intratumoral CD8 T cells, (L) of which PD-1+, (M) granzyme B+ (GrzB+), (N) PD-1+ TCF-1+ stem-like, and (O) PD-1+ TCF-1− progeny with (P) cytotoxic effector functions (n = 4; box plots represent median, minimum/maximum, and individual points). Statistical comparisons were performed using one-way ANOVA with the Tukey multiple comparison test (*, P < 0.05; **, P < 0.01).
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Tobemstomig maintains long-term PD-1+ TCF-1+ CD8 T cells and their progeny in the tumor. In vivo efficacy study and immunopharmacodynamic in human PD-1 and human LAG-3 double transgenic mice bearing subcutaneous Panc02-H7-Fluc tumors treated for 3 weeks with the indicated treatments. Tumor growth curves in mice receiving (A) mu-tobemstomig, (B) mu-nivolumab, (C) mu-relatlimab–like anti–LAG-3, and (D) mu-nivolumab in combination with mu-relatlimab–like anti–LAG-3 (n = 10 mice per treatment group, mean ± SEM). E, Amount of intratumoral T cells, (F) amount of intratumoral CD4 T cells, (G) frequency of Tconv cells (CD4+ FOXP3−), (H) frequency of Tregs (CD4+ FOXP3+), (I) Tconv:Treg ratio, (J) CD8:Treg ratio within the tumor of mice sacrificed on day 28, (K) amount of intratumoral CD8 T cells, (L) of which PD-1+, (M) granzyme B+ (GrzB+), (N) PD-1+ TCF-1+ stem-like, and (O) PD-1+ TCF-1− progeny with (P) cytotoxic effector functions (n = 4; box plots represent median, minimum/maximum, and individual points). Statistical comparisons were performed using one-way ANOVA with the Tukey multiple comparison test (*, P < 0.05; **, P < 0.01).
- Open Access
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Tobemstomig is not internalized or shaved by macrophages and simultaneously binds/blocks PD-1 and LAG-3 on the same cell resulting in preferential targeting of Tconv cells over Tregs rescuing them from Treg suppression. A, Tobemstomig structure. B, Frequency of in vitro activated, polyclonal human AF647+ CD4 T cells upon exposure for 30 minutes to increasing concentrations of AF647-labeled tobemstomig. Part of the PD-1+ LAG-3+ T cells were pretreated with competing PD-1 antibody or LAG-3 antibody to prevent PD-1– or LAG-3–mediated targeting of tobemstomig (n = 4 healthy donors, two independent experiments; mean ± SEM). C, Relative luminescence unit of PD-1 and LAG-3 Jurkat reporter cell line upon exposure to PD-1 and LAG-3 blocking antibodies (n = 3, three independent experiments; mean ± SEM). aLAG-3, anti–LAG-3; aPD-1, anti–PD-1. D, Percentage of internalized construct by polyclonally activated CD4 T cells after 3 hours of incubation at 37°C detected via flow cytometry (n = 4 healthy donors, four independent experiments; box plots represent median, minimum/maximum, and individual points). E, Ratio of construct on cell membrane vs. cytoplasm of polyclonally activated CD4 T cells measured via confocal microscopy. The intensity of the fluorescent signal from the membrane ROI of targeted cells was divided by the intensity of the fluorescent signal from the cytoplasm ROI of the same cells (n = 3 healthy donors, three independent experiments; box plots represent median and minimum/maximum). F, Representative confocal images depicting assessed constructs on single polyclonally activated CD4 T cells after 15 minutes and 3 hours of incubation. T cells labeled with CMFDA (green) during incubation with labeled antibodies (purple). One-way ANOVA with uncorrected Fisher's least significant difference (LSD) (*, P < 0.05; **, P < 0.01). G, Intensity signal of the fluorescent antibodies from Imaris plotted over time. The dataset was normalized over control (parental anti–PD-1) to define a percentage of loss of signal from the T cells defined as the percentage of shaving. A linear regression was then calculated based on normalized data. H, FACS histogram plots of binding competition of directly conjugated tobemstomig, parental PD-1 antibody, LAG-3 antibody, or atezolizumab to human CD4 Tconv cells vs. Tregs, cultured together, from one representative donor of three. I, ΔMFI of human CD4 Tconv cells and Tregs stained with either labeled tobemstomig, parental PD-1 antibody, parental LAG-3 antibody, or atezolizumab (n = 3 healthy donors, median). J, Amount of PD-1, LAG-3, and PD-L1 receptors per T cell on Tconv cells and Tregs (n = 4 healthy donors; box plots represent median, minimum/maximum, and individual points). K, Treg suppression of Tconv granzyme B (GrzB) secretion in the presence of 66,000 pmol/L of the indicated treatments (n = 10 healthy donors, five independent experiments; median). Two-way ANOVA with the Tukey multiple comparison test (*, P < 0.05; **, P < 0.01; ****, P < 0.0001). UT, untreated.
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Tobemstomig is not internalized or shaved by macrophages and simultaneously binds/blocks PD-1 and LAG-3 on the same cell resulting in preferential targeting of Tconv cells over Tregs rescuing them from Treg suppression. A, Tobemstomig structure. B, Frequency of in vitro activated, polyclonal human AF647+ CD4 T cells upon exposure for 30 minutes to increasing concentrations of AF647-labeled tobemstomig. Part of the PD-1+ LAG-3+ T cells were pretreated with competing PD-1 antibody or LAG-3 antibody to prevent PD-1– or LAG-3–mediated targeting of tobemstomig (n = 4 healthy donors, two independent experiments; mean ± SEM). C, Relative luminescence unit of PD-1 and LAG-3 Jurkat reporter cell line upon exposure to PD-1 and LAG-3 blocking antibodies (n = 3, three independent experiments; mean ± SEM). aLAG-3, anti–LAG-3; aPD-1, anti–PD-1. D, Percentage of internalized construct by polyclonally activated CD4 T cells after 3 hours of incubation at 37°C detected via flow cytometry (n = 4 healthy donors, four independent experiments; box plots represent median, minimum/maximum, and individual points). E, Ratio of construct on cell membrane vs. cytoplasm of polyclonally activated CD4 T cells measured via confocal microscopy. The intensity of the fluorescent signal from the membrane ROI of targeted cells was divided by the intensity of the fluorescent signal from the cytoplasm ROI of the same cells (n = 3 healthy donors, three independent experiments; box plots represent median and minimum/maximum). F, Representative confocal images depicting assessed constructs on single polyclonally activated CD4 T cells after 15 minutes and 3 hours of incubation. T cells labeled with CMFDA (green) during incubation with labeled antibodies (purple). One-way ANOVA with uncorrected Fisher's least significant difference (LSD) (*, P < 0.05; **, P < 0.01). G, Intensity signal of the fluorescent antibodies from Imaris plotted over time. The dataset was normalized over control (parental anti–PD-1) to define a percentage of loss of signal from the T cells defined as the percentage of shaving. A linear regression was then calculated based on normalized data. H, FACS histogram plots of binding competition of directly conjugated tobemstomig, parental PD-1 antibody, LAG-3 antibody, or atezolizumab to human CD4 Tconv cells vs. Tregs, cultured together, from one representative donor of three. I, ΔMFI of human CD4 Tconv cells and Tregs stained with either labeled tobemstomig, parental PD-1 antibody, parental LAG-3 antibody, or atezolizumab (n = 3 healthy donors, median). J, Amount of PD-1, LAG-3, and PD-L1 receptors per T cell on Tconv cells and Tregs (n = 4 healthy donors; box plots represent median, minimum/maximum, and individual points). K, Treg suppression of Tconv granzyme B (GrzB) secretion in the presence of 66,000 pmol/L of the indicated treatments (n = 10 healthy donors, five independent experiments; median). Two-way ANOVA with the Tukey multiple comparison test (*, P < 0.05; **, P < 0.01; ****, P < 0.0001). UT, untreated.